Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC101 phase 3b study in chronic kidney disease with metabolic acidosis
NL-OMON55510Phase 3Active, not recruiting
- Sponsor
- Tricida, Inc.
- Start
- May 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic acidosis and chronic kidney disease (CKD) comparing TRC101 with Placebo (2 arms). Primary endpoint: Progression of chronic kidney disease. Started May 2019; status: active, not recruiting.
02
Drugs
veverimer
03
Conditions
metabolic acidosischronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON55510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55510.